Rodríguez Zorrilla Samuel, Pérez-Sayans Mario, Fais Stefano, Logozzi Mariantonia, Gallas Torreira Mercedes, García García Abel
Oral Medicine, Oral Surgery and Implantology Unit, School of Medicine and Dentistry, University of Santiago de Compostela, 15782 Galicia, Spain.
Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, 15706 Coruña, Spain.
Cancers (Basel). 2019 Mar 26;11(3):429. doi: 10.3390/cancers11030429.
To evaluate the relationship between the plasmatic CD63 and CAV1 positive exosome levels, in patients with OSCC before and after surgical treatment and to correlate it with their overall survival.
A double-blind pilot study over 10 patients OSCC and T4 stage without distant metastases or local bone invasion has been performed. The average follow-up period was 37.64 months (34.3⁻40.84). We obtained 2 plasma tubes of 1 mL each before surgery and 7 days after surgery. Before performing the immunocapture-based analysis, EVs (Extracellular Vesicles) were isolated from the plasma and characterized with western blot analysis.
Mean values of CD63 positive plasmatic exosomes (EXO-CD63) after surgery decreased from 750.88 ± 286.67 to 541.71 ± 244.93 ( = 0.091). On the other hand, CAV-1 positive plasmatic exosomes (EXO-CAV-1) increased after surgery from 507 ± 483.39 to 1120.25 ± 1151.17 ( = 0.237). Patients with EXO-CD63 levels lower than the mean global value before the surgery had a survival of 36.04 months compared with the group with EXO-CD63 higher than the average who only survived 12.49 ± 1.67 months from the diagnosis, = 0.225. When EXO-CAV-1 levels before surgery was lower than the average (813.94 ± 801.21) overall survival was 24.69 ± 22.23 months in contrast when it was higher that was only 11.64 months, = 0.157. Patients with lower EXO-CD63 levels after surgery lived an average of 23.84 ± 23.9 months, while those with higher plasmatic levels of EXO-CD63 live 13.35 months, = 0.808. When EXO-CAV-1 levels after surgery were lower, the average overall survival was 20.344 ± 15.40 months, in contrast when the EXO-CAV-1 levels were higher showing rather an estimate survival expectation of 1.64 months.
Surgical treatment induced a dramatic reduction of the plasmatic levels of exosomes expressing CD63 as early as 1 week after resection. This first result suggests that the tumour mass is responsible of the high levels of circulating exosomes detected in cancer patients. At the same time point exosome expressing CAV-1 increased, possibly due to the inflammatory reaction immediately after surgery. Lastly, statistical analysis showed that lower levels of plasmatic exosomes both before and after surgery correlated with a better life expectancy of OSCC patients. Hopefully, this approach will prove useful in the clinical follow-up of cancer patients.
评估口腔鳞状细胞癌(OSCC)患者手术治疗前后血浆中CD63和CAV1阳性外泌体水平之间的关系,并将其与患者的总生存期相关联。
对10例无远处转移或局部骨侵犯的OSCC和T4期患者进行了一项双盲试点研究。平均随访期为37.64个月(34.3 - 40.84)。我们在手术前和手术后7天各采集了2管1 mL血浆。在进行基于免疫捕获的分析之前,从血浆中分离出细胞外囊泡(EVs),并通过蛋白质印迹分析进行表征。
手术后CD63阳性血浆外泌体(EXO - CD63)的平均值从750.88±286.67降至541.71±244.93(P = 0.091)。另一方面,CAV - 1阳性血浆外泌体(EXO - CAV - 1)在手术后从507±483.39增加到1120.25±1151.17(P = 0.237)。EXO - CD63水平低于手术前平均总体值的患者生存期为36.04个月,而EXO - CD63高于平均值的组从诊断起仅存活12.49±1.67个月,P = 0.225。当手术前EXO - CAV - 1水平低于平均值(813.94±801.21)时,总生存期为24.69±22.23个月,而当其高于平均值时仅为11.64个月,P = 0.157。手术后EXO - CD63水平较低的患者平均存活23.84±23.9个月,而血浆EXO - CD63水平较高的患者存活13.35个月,P = 0.808。当手术后EXO - CAV - 1水平较低时,平均总生存期为20.344±15.40个月,相比之下,当EXO - CAV - 1水平较高时,估计生存期仅为1.64个月。
手术治疗在切除后1周内即导致表达CD63的血浆外泌体水平显著降低。这一初步结果表明肿瘤块是癌症患者中检测到的循环外泌体高水平的原因。在同一时间点,表达CAV - 1的外泌体增加,可能是由于手术刚结束后的炎症反应。最后,统计分析表明手术前后血浆外泌体水平较低与OSCC患者更好的预期寿命相关。希望这种方法在癌症患者的临床随访中被证明是有用的。